title: [Benfluorex and valvular heart disease].
abstract: Benfluorex is responsible of restrictive organic valvular regurgitations via one of its metabolites, the norfenfluramine. It has been withdrawn from the european market in June 2010. In France, about five millions of people have been exposed to benfluorex since its market launch in 1976. At the time of its market withdrawn, over 300,000 patients in France were taking the drug. Aortic and mitral valves are the most frequent involved. The prevalence of this type of valve damage is not yet known with accuracy. Severe regurgitations appear to be rare (less than one case per thousand exposed patients-year).
authors: Département de cardiologie, Inserm, ERI 12, CHU d'Amiens, Amiens, France. Tribouilloy.Christophe@chu-amiens.fr
authors: Christophe
authors: C
authors: Tribouilloy
authors: Antoine
authors: A
authors: Jeu
authors: Sylvestre
authors: S
authors: Maréchaux
authors: Yannick
authors: Y
authors: Jobic
authors: Dan
authors: D
authors: Rusinaru
authors: Michel
authors: M
authors: Andréjak
mesh_terms: D001022:Aortic Valve Insufficiency / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D001067:Appetite Depressants / Q000627:therapeutic use / Q000633:toxicity*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004452:Echocardiography; D005260:Female; D005277:Fenfluramine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity; D005500:Follow-Up Studies; D005602:France; D006351:Heart Valves / Q000187:drug effects / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D009642:Norfenfluramine / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D016032:Randomized Controlled Trials as Topic; D056737:Safety-Based Drug Withdrawals
chemical_list: D001067:Appetite Depressants; D009642:Norfenfluramine; D005277:Fenfluramine; C001584:benfluorex